The Group has three reportable segments, as discussed below, which are based on information provided to the Board of Directors, which is deemed to be the Group's chief operating decision maker. Several operating segments which have similar economic characteristics have been aggregated into the reporting segments. In undertaking this aggregation the assessment determined that the aggregated segments have similar products, production processes, customers and overall regulatory environment.

The European Pharmaceuticals Segment comprises Dechra Veterinary Products EU, Apex Laboratories Pty Limited (Apex), Genera and Dechra Pharmaceuticals Manufacturing. This Segment operates internationally and manufactures and markets Companion Animal, Equine and Food producing Animal Products. This Segment also includes third party manufacturing and other non-core activities sales. The Segment expanded during the year with the acquisition of the trade and assets of Apex.

The North American Pharmaceuticals Segment consists of Dechra Veterinary Products US, Putney, Dechra Veterinary Products Canada, and Dechra-Brovel, which sells Companion Animal, Equine Products and Food producing Animal Products in those territories. The Segment also includes our manufacturing unit based in Melbourne, Florida.

The Pharmaceuticals Research and Development Segment includes all of the Group's pharmaceutical research and development activities. From a Board perspective, this Segment has no revenue income.

Reconciliation of reportable segment revenues, profit or loss and liabilities and other material items:

2017
£000
2016
£000
Revenue by segment
European Pharmaceuticals— total226,930188,859
NA Pharmaceuticals— total132,34558,703
359,275247,562
Operating profit/(loss) by segment
European Pharmaceuticals60,70651,653
NA Pharmaceuticals43,19517,500
Pharmaceuticals Research and Development(14,978)(10,355)
Segment operating profit88,92358,798
Corporate and other unallocated costs(7,574)(5,941)
Underlying operating profit81,34952,857
Amortisation of acquired intangibles(40,444)(20,149)
Impairment of acquired intangibles and associated deferred consideration(1,675)
Impairment of assets available for sale(602)
Fair value uplift of inventory acquired through business combinations(4,225)(6,070)
Rationalisation costs(809)(1,581)
Expenses relating to acquisition activities(2,055)(3,889)
Total operating profit33,21419,493
Finance income80521
Finance expense(5,298)(4,966)
Share of losses in investment accounted for using the equity method(159)
Profit before taxation28,56214,548
Total liabilities by segment
European Pharmaceuticals(73,738)(47,498)
NA Pharmaceuticals(20,165)(15,890)
Pharmaceuticals Research and Development(404)(776)
Segment liabilities(94,307)(64,164)
Corporate loans and revolving credit facility(181,143)(155,741)
Corporate accruals and other payables(8,197)(6,494)
Current and deferred tax liabilities(51,785)(52,817)
(335,432)(279,216)
Revenue by product category
CAP223,826137,686
Equine27,24620,518
FAP47,31538,101
Diets27,45724,383
Other33,43126,874
359,275247,562
Additions to intangible non-current assets by segment (including through business combinations)
European Pharmaceuticals64,50215,809
NA Pharmaceuticals4,409161,011
Pharmaceuticals Research and Development1,37355
Corporate and central costs1042,404
70,388179,279
Additions to Property, Plant and Equipment by segment (including through business combinations)
European Pharmaceuticals10,11719,443
NA Pharmaceuticals567924
Pharmaceuticals Research and Development8236
Corporate and central costs69
10,76620,472
Depreciation and amortisation by segment
European Pharmaceuticals22,69718,984
NA Pharmaceuticals23,3675,901
Pharmaceuticals Research and Development500345
Corporate and central costs73585
47,29925,315
The total depreciation and amortisation charge is made up of the following:
Non-underlying
Amortisation — selling, general and administrative expenses29,00320,149
Amortisation — research and development expenditure11,441
40,44420,149
Underlying
Amortisation1,9421,403
Depreciation4,9133,763
6,8555,166

Geographical Information

The following table shows revenue based on the geographical location of customers and non-current assets based on the country of domicile of the entity holding the asset:

2017
Revenue
£000
2017
Non-current assets
£000
2016
Revenue
£000
2016
Non-current assets
£000
UK56,31715,56754,42019,624
Germany37,4102,40434,1052,326
Rest of Europe113,118192,46191,794162,138
USA124,128193,16653,912206,364
Rest of World28,30249,49513,3312,990
359,275453,093247,562393,442